SCM
BCAX

Sterling Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Sterling Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.39K Sell
249
-751
-75% -$16.8K ﹤0.01% 2391
2026
Q1 		$19.9K Sell
1,000
-720
-42% -$12.4K ﹤0.01% 2031
2025
Q4 		$28.9K Sell
1,720
-506
-23% -$8.64K ﹤0.01% 2032
2025
Q3 		$35.1K Buy
2,226
+1,352
+155% +$15.1K ﹤0.01% 1892
2025
Q2 		$8.12K Buy
874
+712
+440% +$8.49K ﹤0.01% 2260
2025
Q1 		$2.11K Sell
162
-114
-41% -$1.51K ﹤0.01% 2574
2024
Q4 		$4.81K Buy
+276
New +$5.74K ﹤0.01% 2480

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sterling Capital Management's BCAX Position: Q2 2026 in Review

Sterling Capital Management reduced its Bicara Therapeutics (BCAX) stake by 75% in Q2 2026, selling an estimated $16.8K and leaving 249 shares worth $7.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2391.

Sterling Capital Management first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. The position peaked at $35.1K in Q3 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Sterling Capital Management held 249 shares of Bicara Therapeutics worth $7.39K as of Q2 2026.
  • Sterling Capital Management sold 751 Bicara Therapeutics shares in Q2 2026, an estimated $16.8K.
  • Bicara Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2391 holding.
  • Sterling Capital Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Bicara Therapeutics position peaked at $35.1K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.